Menu
Your Cart

Verrukutan solution nakozh. 5mg/g +100mg/g fl. 13 ml

Verrukutan solution nakozh. 5mg/g +100mg/g fl. 13 ml
Verrukutan solution nakozh. 5mg/g +100mg/g fl. 13 ml
Verrukutan solution nakozh. 5mg/g +100mg/g fl. 13 ml
Verrukutan solution nakozh. 5mg/g +100mg/g fl. 13 ml
Verrukutan solution nakozh. 5mg/g +100mg/g fl. 13 ml
$35.79
  • Stock: In Stock
  • Model: 177019

0% Customers recommend this product

  • 5 Awesome
    0%
  • 4 Great
    0%
  • 3 Average
    0%
  • 2 Bad
    0%
  • 1 Poor
    0%

Reviews Over Verrukutan solution nakozh. 5mg/g +100mg/g fl. 13 ml

  • (0)

Total Reviews (0)
click here write review to add review for this product.



Description

Verrukutan is a dermatological medicament against warts and callosities.

Indications - common warts (especially warts on sites of a foot of whom the biggest loading is the share), flat juvenile warts of extremities.

Structure

contains
  • 1 g of solution 5 mg of a flyuorouratsil and 100 mg of salicylic acid;
  • other components: a dimethyl sulfoxide, ethanol waterless, ethyl acetate, guncotton, weed (butyl-methacrylate-to-methylmethacrylate) (80: 20).

Contraindication

Hypersensitivity to active ingredients or to any excipients.

Verrukutan should not be applied to women during feeding by a breast, to pregnancy and women whose pregnancy cannot be excluded with definiteness.

Verrukutan should not be applied to babies and patients with a renal failure.

Route of administration Usually verrukutan should apply

to

from two to three times a day on each wart. The usual duration of application is 6 weeks. Means should be put regularly every day. After completion of successful therapy the treatment should be prolonged for 1 week.

Feature of application

to

On skin zones with the warts having thin epidermis, means it is necessary to put more rare and the course of treatment should be controlled more often as salicylic acid as a part of Verrukutan renders powerful effect of mitigation of a corneal layer of epidermis that can cause emergence of hems.

On the warts inclined to keratinization, sometimes it is reasonable to plaster previously with salicylic acid.

Pregnant

Verrukutan should not be applied to women during pregnancy.

Children

Verrukutan should not be applied to babies.

Drivers

Verrukutan does not influence or has insignificant impact on ability to steer motor transport or other mechanisms.

Overdose

Early symptoms of salitsilatny intoxication can take place at serumal levels more than 30 mg/dl.

They are shown by a ring in ears, sonitus with decrease in hearing, nasal bleeding, nausea, vomiting, irritation and dryness of mucous.

Side effects

from nervous system: headaches.

from organs of sight: xerophthalmus, an itch in eyes, the raised slezootdeleniye.

from skin: peeling.

General violations and violations in the injection site: in the place of application: an erythema, inflammation, irritation (including burning sensation), pain, an itch.

Storage conditions

to Store

at a temperature not above 30 °C. Not to cool and not to freeze. To store out of children's reach.

Specifications

Characteristics
Active ingredients Salicylic acid, Flyuorouratsil
Amount of active ingredient 5 mg/g + 100 mg/g
Applicant Mibe
Code of automatic telephone exchange The Means D11AF applied to removal of warts and callosities
Interaction with food It doesn't matter
Light sensitivity Not sensitive
Market status Traditional
Origin Chemical
Prescription status According to the prescription
Primary packing bottle
Producer IIB OF GMBH ARTSNAYMITTEL
Quantity in packing 1 bottle
Release form solution for external use
Route of administration External
Sign Import
Storage temperature from 5 °C to 25 °C
Trade name Verrukutan